Is Regression of Left Ventricular Hypertrophy Really a Good Thing for Patients With Hypertrophic Cardiomyopathy?: The Emerging Mavacamten Story

Am J Cardiol. 2021 May 15:147:145-146. doi: 10.1016/j.amjcard.2021.01.034. Epub 2021 Feb 4.

Authors

Barry J Maron¹, Ethan J Rowin², Martin S Maron²

Affiliations

¹ HCM Institute, Tufts Medical Center, Boston, Massachusetts. Electronic address: Barrymaron1@gmail.com.
² HCM Institute, Tufts Medical Center, Boston, Massachusetts.

PMID: 33549527
DOI: 10.1016/j.amjcard.2021.01.034

No abstract available

Publication types

Editorial

MeSH terms

Benzylamines / therapeutic use*
Cardiomyopathy, Hypertrophic / complications*
Cardiomyopathy, Hypertrophic / pathology
Humans
Hypertrophy, Left Ventricular / complications*
Hypertrophy, Left Ventricular / drug therapy
Hypertrophy, Left Ventricular / pathology*
Uracil / analogs & derivatives*
Uracil / therapeutic use

Substances

Benzylamines
MYK-461
Uracil